Date  Sort Arrow Headline
Oct 18, 2021 Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
Aug 9, 2021 Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 5, 2021 Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
Aug 2, 2021 Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
Jul 8, 2021 Celcuity to Participate in the William Blair Biotech Focus Conference
Jun 28, 2021 Celcuity Announces Pricing of Follow-on Offering
Jun 28, 2021 Celcuity Announces Launch of Follow-on Offering
Jun 9, 2021 Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
May 10, 2021 Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
Apr 26, 2021 Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
Apr 12, 2021 Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
Apr 8, 2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus IbranceĀ® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
Apr 8, 2021 Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
Mar 16, 2021 Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
Mar 1, 2021 Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock